复宏汉霖PD-1抗体H药再次大超预期。过去H药另辟蹊径,凭借在一线广泛期小细胞肺癌(ES-SCLC)创历史的15.8个月mOS数据,从国内后发的PD-1产品进阶为2024年销售突破13亿人民币的重磅单品。如今,H药通过胃癌围手术期三期研究的成功,开始全新的成长征程。10月9日,复宏汉霖宣布H药联合化疗新辅助/单药辅助治疗胃癌的III期临床(ASTRUM-006)期中分析达到了主要研究终点无事件...
Source Link复宏汉霖PD-1抗体H药再次大超预期。过去H药另辟蹊径,凭借在一线广泛期小细胞肺癌(ES-SCLC)创历史的15.8个月mOS数据,从国内后发的PD-1产品进阶为2024年销售突破13亿人民币的重磅单品。如今,H药通过胃癌围手术期三期研究的成功,开始全新的成长征程。10月9日,复宏汉霖宣布H药联合化疗新辅助/单药辅助治疗胃癌的III期临床(ASTRUM-006)期中分析达到了主要研究终点无事件...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.